Condition: Respiratory Synctial Virus · Asthma Childhood · Sponsor: University of British Columbia
Respiratory Syncytial Virus (RSV) is a main global cause of respiratory illness and death in infants. Previous infant vaccine trials have failed to demonstrate protection. Moreover, RSV infection during early infancy, particularly in infants younger than 4 months of age, is associated with more severe disease, reduced immune protection, and an increased risk of developing childhood asthma. This study aim to investigate the immunological and long-term health effects of a first exposure to RSV early (\<4 months) versus late (\>6-9 months) in infancy.
This description comes directly from the study's public registry record.
Pascal Lavoie, MDCM PhD FRCPC · 604-875-2135 · plavoie@bcchr.ca
Allison Watts, PhD · 604-875-2000 · awatts@bcchr.ca
Always discuss trial participation with your own doctor first.
| BC Women's Hospital and Health Centre | Vancouver, British Columbia, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07653347